Vicki L. Sato
CIK: 0001197020
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (25 total)
- Jun 18, 2026ALLO
Allogene Therapeutics, Inc.
Award(A)DirectRestricted Stock Unit
95.4K shares- - May 1, 2026VIR
Vir Biotechnology, Inc.
Sale(S)Direct22K shares at avg. $10.05$221K - Apr 1, 2026VIR
Vir Biotechnology, Inc.
Sale(S)Direct22K shares at avg. $9.07$200K - Mar 2, 2026VIR
Vir Biotechnology, Inc.
Sale(S)Direct200 shares at avg. $9.98$2K - Mar 2, 2026VIR
Vir Biotechnology, Inc.
Sale(S)Direct21.8K shares at avg. $9.50$207K - Feb 24, 2026VIR
Vir Biotechnology, Inc.
Sale(S)Direct42.2K shares at avg. $9.75$411K - Feb 24, 2026VIR
Vir Biotechnology, Inc.
Sale(S)Direct200 shares at avg. $10.26$2K - Feb 24, 2026VIR
Vir Biotechnology, Inc.
Exercise(M)Direct42.4K shares at avg. $1.49$63K - Feb 2, 2026VIR
Vir Biotechnology, Inc.
Sale(S)Direct22K shares at avg. $7.71$170K - Jan 2, 2026VIR
Vir Biotechnology, Inc.
Sale(S)Direct22K shares at avg. $5.93$130K - Dec 1, 2025VIR
Vir Biotechnology, Inc.
Sale(S)Direct22K shares at avg. $6.00$132K - Nov 3, 2025VIR
Vir Biotechnology, Inc.
Sale(S)Direct22K shares at avg. $5.64$124K - Oct 1, 2025VIR
Vir Biotechnology, Inc.
Sale(S)Direct22K shares at avg. $5.84$128K - Sep 2, 2025VIR
Vir Biotechnology, Inc.
Sale(S)Direct22K shares at avg. $4.99$110K - Aug 1, 2025VIR
Vir Biotechnology, Inc.
Sale(S)Direct22K shares at avg. $4.99$110K - Jul 1, 2025VIR
Vir Biotechnology, Inc.
Sale(S)Direct22K shares at avg. $5.10$112K - Jun 18, 2025ALLO
Allogene Therapeutics, Inc.
Award(A)DirectStock Option (Right to buy)
144.4K shares- - May 30, 2025VIR
Vir Biotechnology, Inc.
Award(A)Direct8K shares- - Jan 8, 2025VIR
Vir Biotechnology, Inc.
Sale(S)Direct11K shares at avg. $12.52$137K - Jan 2, 2025DNLI
Denali Therapeutics Inc.
Sale(S)Direct3.1K shares at avg. $20.91$64K - Nov 7, 2024DNLI
Denali Therapeutics Inc.
Sale(S)Direct1K shares at avg. $30.00$31K - Nov 1, 2024DNLI
Denali Therapeutics Inc.
Sale(S)Direct3.1K shares at avg. $27.07$83K - Sep 13, 2024DNLI
Denali Therapeutics Inc.
Sale(S)Direct1K shares at avg. $30.00$31K - Sep 3, 2024DNLI
Denali Therapeutics Inc.
Sale(S)Direct100 shares at avg. $25.37$3K - Sep 3, 2024DNLI
Denali Therapeutics Inc.
Sale(S)Direct3K shares at avg. $24.99$74K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 18, 2026 |  ALLO Allogene Therapeutics, Inc. | Award(A) Restricted Stock Unit | 95,400 | - | - | Direct |
| May 1, 2026 |  VIR Vir Biotechnology, Inc. | Sale(S) | 22,000 | $10.05 | $221,025 | Direct |
| Apr 1, 2026 | VIR Vir Biotechnology, Inc. | Sale(S) | 22,000 | $9.07 | $199,617 | Direct |
| Mar 2, 2026 | VIR Vir Biotechnology, Inc. | Sale(S) | 200 | $9.98 | $1,996 | Direct |
| Mar 2, 2026 | VIR Vir Biotechnology, Inc. | Sale(S) | 21,800 | $9.50 | $207,185 | Direct |
| Feb 24, 2026 | VIR Vir Biotechnology, Inc. | Sale(S) | 42,177 | $9.75 | $411,314 | Direct |
| Feb 24, 2026 | VIR Vir Biotechnology, Inc. | Sale(S) | 200 | $10.26 | $2,052 | Direct |
| Feb 24, 2026 | VIR Vir Biotechnology, Inc. | Exercise(M) | 42,377 | $1.49 | $62,930 | Direct |
| Feb 2, 2026 | VIR Vir Biotechnology, Inc. | Sale(S) | 22,000 | $7.71 | $169,671 | Direct |
| Jan 2, 2026 | VIR Vir Biotechnology, Inc. | Sale(S) | 22,000 | $5.93 | $130,383 | Direct |
| Dec 1, 2025 | VIR Vir Biotechnology, Inc. | Sale(S) | 22,000 | $6.00 | $132,070 | Direct |
| Nov 3, 2025 | VIR Vir Biotechnology, Inc. | Sale(S) | 22,000 | $5.64 | $124,047 | Direct |
| Oct 1, 2025 | VIR Vir Biotechnology, Inc. | Sale(S) | 22,000 | $5.84 | $128,396 | Direct |
| Sep 2, 2025 | VIR Vir Biotechnology, Inc. | Sale(S) | 22,000 | $4.99 | $109,811 | Direct |
| Aug 1, 2025 | VIR Vir Biotechnology, Inc. | Sale(S) | 22,000 | $4.99 | $109,699 | Direct |
| Jul 1, 2025 | VIR Vir Biotechnology, Inc. | Sale(S) | 22,000 | $5.10 | $112,207 | Direct |
| Jun 18, 2025 | ALLO Allogene Therapeutics, Inc. | Award(A) Stock Option (Right to buy) | 144,400 | - | - | Direct |
| May 30, 2025 | VIR Vir Biotechnology, Inc. | Award(A) | 8,000 | - | - | Direct |
| Jan 8, 2025 | VIR Vir Biotechnology, Inc. | Sale(S) | 10,960 | $12.52 | $137,219 | Direct |
| Jan 2, 2025 |  DNLI Denali Therapeutics Inc. | Sale(S) | 3,080 | $20.91 | $64,403 | Direct |
| Nov 7, 2024 | DNLI Denali Therapeutics Inc. | Sale(S) | 1,020 | $30.00 | $30,600 | Direct |
| Nov 1, 2024 | DNLI Denali Therapeutics Inc. | Sale(S) | 3,080 | $27.07 | $83,376 | Direct |
| Sep 13, 2024 | DNLI Denali Therapeutics Inc. | Sale(S) | 1,020 | $30.00 | $30,600 | Direct |
| Sep 3, 2024 | DNLI Denali Therapeutics Inc. | Sale(S) | 100 | $25.37 | $2,537 | Direct |
| Sep 3, 2024 | DNLI Denali Therapeutics Inc. | Sale(S) | 2,980 | $24.99 | $74,470 | Direct |
1-25 of 25 transactions
About SATO VICKI L
SATO VICKI L (SEC CIK 0001197020) files insider reports with the SEC as Director of Allogene Therapeutics, Inc. (ALLO), Director of Vir Biotechnology, Inc. (VIR) and Director of Denali Therapeutics Inc. (DNLI).
Signal8 holds 21 ownership filings by SATO VICKI L, all Form 4s, filed between Sep 4, 2024 and Jun 23, 2026. Those filings report 25 transactions, from Sep 3, 2024 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on SATO VICKI L's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by SATO VICKI L
- Jun 18, 2026: Grant or award of ALLO derivative securities (Form 4, code A).
- May 1, 2026: Open-market sale of VIR shares (Form 4, code S).
- Apr 1, 2026: Open-market sale of VIR shares (Form 4, code S).
- Mar 2, 2026: Open-market sales of VIR shares (2 lines, Form 4, code S).
- Feb 24, 2026: Open-market sales of VIR shares (2 lines, Form 4, code S).
Other insiders filing for Allogene Therapeutics, Inc. (ALLO)
- Parker Geoffrey M., CHIEF FINANCIAL OFFICER
- Douglas Earl Martin, SVP, General Counsel
- Roberts Zachary, President and CEO
- Kazam Joshua A, Director
- MESSEMER DEBORAH M., Director
- Mayo Stephen, Director